Human complement receptor type 2 (CR2/CD21) transgenic mice provide an in vivo model to study immunoregulatory effects of receptor antagonists

Molecular Immunology

Volumn 48, Issue 6-7, 2011, Pages 883-894

  Kulik, Liudmila ^a,b   Chen, Kuan ^a,b   Huber, Brigitte T ^c   Holers, V Michael ^a,b  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF COLORADO   (United States)

^c TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

B cells; C3d; Complement receptor; Immune responses; Monoclonal antibody; Transgenic mice

Indexed keywords

CALCIUM ION; COMPLEMENT COMPONENT C3D RECEPTOR; COMPLEMENT INHIBITOR; COMPLEMENT RECEPTOR; COMPLEMENT RECEPTOR 2; IMMUNOGLOBULIN G1 ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 171; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY COMBINING SITE; ANTIBODY PRODUCTION; ANTIGEN SPECIFICITY; ARTICLE; B LYMPHOCYTE; B LYMPHOCYTE ACTIVATION; BACTERIAL ARTIFICIAL CHROMOSOME; CALCIUM CELL LEVEL; CALCIUM TRANSPORT; CONTROLLED STUDY; HUMORAL IMMUNITY; IMMUNIZATION; IMMUNOREGULATION; IN VIVO STUDY; LYMPHOCYTE COUNT; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SHEEP ERYTHROCYTE; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TRANSGENIC MOUSE;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD19; B-LYMPHOCYTES; CHROMOSOMES, ARTIFICIAL, BACTERIAL; CLONAL ANERGY; ERYTHROCYTES; HUMANS; INJECTIONS; LYMPHOCYTE COUNT; LYMPHOCYTE DEPLETION; MICE; MICE, TRANSGENIC; MODELS, IMMUNOLOGICAL; PERITONEUM; RECEPTORS, ANTIGEN, B-CELL; RECEPTORS, COMPLEMENT 3D; SHEEP; SIGNAL TRANSDUCTION; TRANSGENES;

BACTERIA (MICROORGANISMS); MUS; MUS MUSCULUS; OVIS ARIES;

EID: 79951552443     PISSN: 01615890     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.molimm.2010.12.019     Document Type: Article

References (91)

1. Ahearn J.M., Fearon D.T. Structure and function of the complement receptors, CR1 (CD35) and CR2 (CD21). Adv. Immunol. 1989, 46:183-219.
2. Asokan R., Hua J., Young K.A., Gould H.J., Hannan J.P., Kraus D.M., Szakonyi G., Grundy G.J., Chen X.S., Crow M.K., Holers V.M. Characterization of human complement receptor type 2 (CR2/CD21) as a receptor for IFN-alpha: a potential role in systemic lupus erythematosus. J. Immunol. 2006, 177:383-394.
3. Aubry J.P., Pochon S., Gauchat J.F., Nueda-Marin A., Holers V.M., Graber P., Siegfried C., Bonnefoy J.Y. CD23 interacts with a new functional extracytoplasmic domain involving N-linked oligosaccharides on CD21. J. Immunol. 1994, 152:5806-5813.
4. Aubry J.P., Pochon S., Graber P., Jansen K.U., Bonnefoy J.Y. CD21 is a ligand for CD23 and regulates IgE production. Nature 1992, 358:505-507.
5. Barrington R.A., Pozdnyakova O., Zafari M.R., Benjamin C.D., Carroll M.C. B lymphocyte memory: role of stromal cell complement and FcgammaRIIB receptors. J. Exp. Med. 2002, 196:1189-1199.
6. Barrington R.A., Schneider T.J., Pitcher L.A., Mempel T.R., Ma M., Barteneva N.S., Carroll M.C. Uncoupling CD21 and CD19 of the B-cell coreceptor. Proc. Natl. Acad. Sci. U. S. A 2009, 106:14490-14495.
7. Birrell L., Kulik L., Morgan B.P., Holers V.M., Marchbank K.J. B cells from mice prematurely expressing human complement receptor type 2 are unresponsive to T-dependent antigens. J. Immunol. 2005, 174:6974-6982.
8. Boackle S.A., Holers V.M., Chen X., Szakonyi G., Karp D.R., Wakeland E.K., Morel L. Cr2, a candidate gene in the murine Sle1c lupus susceptibility locus, encodes a dysfunctional protein. Immunity 2001, 15:775-785.
9. Boackle S.A., Morris M.A., Holers V.M., Karp D.R. Complement opsonization is required for presentation of immune complexes by resting peripheral blood B cells. J. Immunol. 1998, 161:6537-6543.
10. Bouillie S., Barel M., Frade R. Signaling through the EBV/C3d receptor (CR2, CD21) in human B lymphocytes: activation of phosphatidylinositol 3-kinase via a CD19-independent pathway. J. Immunol. 1999, 162:136-143.
11. Bradbury L.E., Kansas G.S., Levy S., Evans R.L., Tedder T.F. The CD19/CD21 signal transducing complex of human B lymphocytes includes the target of antiproliferative antibody-1 and Leu-13 molecules. J. Immunol. 1992, 149:2841-2850.
12. Brockman M.A., Verschoor A., Zhu J., Carroll M.C., Knipe D.M. Optimal long-term humoral responses to replication-defective herpes simplex virus require CD21/CD35 complement receptor expression on stromal cells. J. Virol. 2006, 80:7111-7117.
13. Brown S.L., Barrault D.V., Phythian-Adams A., Knight A.M. Lack of induced co-stimulation as a result of complement receptor 2 (CR2) ligation on mouse splenic B cells. Int. Immunol. 2006, 18:69-78.
14. Buhl A.M., Pleiman C.M., Rickert R.C., Cambier J.C. Qualitative regulation of B cell antigen receptor signaling by CD19: selective requirement for P13-kinase activation, inositol-1,4,5-trisphosphate production and Ca2+ mobilization. J. Exp. Med. 1998, 186:1897-1910.
15. Carlsson F., Getahun A., Rutemark C., Heyman B. Impaired antibody responses but normal proliferation of specific CD4+ T cells in mice lacking complement receptors 1 and 2. Scand. J. Immunol. 2009, 70:77-84.
16. Carroll M.C. The role of complement in B cell activation and tolerance. Adv. Immunol. 2000, 74:61-88.
17. Carroll M.C. CD21/CD35 in B cell activation. Semin. Immunol. 1998, 10:279-286.
18. Carroll M.C. The role of complement and complement receptors in the induction and regulation of immunity. Ann. Rev. Immunol. 1998, 16:545-568.
19. Chakravarty L., Zabel M.D., Weis J.J., Weis J.H. Depletion of Lyn kinase from the BCR complex and inhibition of B cell activation by excess CD21 ligation. Intl. Immunol. 2002, 14:139-146.
20. Chen Z.M., Koralev S.B., Gendelman M., Carroll M.C., Kelsoe G. Humoral immune responses in Cr2-/- mice: enhanced affinity maturation but impaired antibody persistence. J. Immunol. 2000, 164:4522-4532.
21. Chung J.B., Silverman M., Monroe J.G. Transitional B cells: step by step towards immune competence. Trends Immunol. 2003, 24:343-349.
22. Cooper N.R., Moore M.D., Nemerow G.R. Immunobiology of CR2, the B lymphocyte receptor for Epstein-Barr virus and the C3d complement fragment. Ann. Rev. Immunol. 1988, 6:85-113.
23. Delcayre A.X., Salas F., Mathur S., Kovats K., Lotz M., Lernhardt W. Epstein-Barr virus/complement C3d receptor is an interferon-α receptor. EMBO J. 1991, 10:919-926.
24. Dempsey P.W., Allison M.E., Akkaraju S., Goodnow C.C., Fearon D.T. C3d of complement as a molecular adjuvant: bridging innate and acquired immunity. Science 1996, 271:348-350.
25. Fang Y., Xu C., Fu Y.-X., Holers V.M., Molina H. Expression of complement receptors 1 and 2 on follicular dendritic cells is necessary for the generation of a strong antigen-specific IgG response. J. Immunol. 1998, 160:5273-5279.
26. Fearon D.T., Carroll M.C. Regulation of B lymphocyte responses to foreign and self-antigens by the CD19/CD21 complex. Annu. Rev. Immunol. 2000, 18:393-422.
27. Fingeroth J.D. Comparative structure and evolution of murine CR2. The homolog of the human C3d/EBV receptor (CD21). J. Immunol. 1990, 144:3458-3467.
28. Fingeroth J.D., Benedict M.A., Levy D.N., Strominger J.L. Identification of murine complement receptor type 2. Proc. Natl. Acad. Sci. U. S. A 1989, 86:242-246.
29. Fingeroth J.D., Weis J.J., Tedder T.F., Strominger J.L., Biro P.A., Fearon D.T. Epstein-Barr virus receptor of human B lymphocytes is the C3d receptor CR2. Proc. Natl. Acad. Sci. U. S. A. 1984, 81:4510-4514.
30. Fischer E., Delibrias C., Kazatchkine M.D. Expression of CR2 (the C3dg/EBV receptor, CD21) on normal human peripheral blood T lymphocytes. J. Immunol. 1991, 146:865-869.
31. Fleming S.D., Shea-Donohue T., Guthridge J.M., Kulik L., Waldschmidt T.J., Gipson M.G., Tsokos G.C., Holers V.M. Mice deficient in complement receptors 1 and 2 lack a tissue injury-inducing subset of the natural antibody repertoire. J. Immunol. 2002, 169:2126-2133.
32. Fremeaux-Bacchi V., Bernard I., Maillet F., Mani J.C., Fontaine M., Bonnefoy J.Y., Kazatchkine M.D., Fischer E. Human lymphocytes shed a soluble form of CD21 (the C3dg/Epstein-Barr virus receptor, CR2) that binds iC3b and CD23. Eur. J. Immunol. 1996, 26:1497-1503.
33. Fujisaku A., Harley J.B., Frank M.B., Gruner B.A., Frazier B., Holers V.M. Genomic organization and polymorphisms of the human C3d/Epstein-Barr virus receptor. J. Biol. Chem. 1989, 264:2118-2125.
34. Gatto D., Pfister T., Jegerlehner A., Martin S.W., Kopf M., Bachmann M.F. Complement receptors regulate differentiation of bone marrow plasma cell precursors expressing transcription factors Blimp-1 and XBP-1. J. Exp. Med. 2005, 201:993-1005.
35. Guthridge J.M., Young K., Gipson M.G., Sarrias M.-R., Szakonyi G., Chen X.S., Malaspina A., Donoghue E., James J.A., Lambris J.D., Moir S.A., Perkins S.J., Holers V.M. Epitope mapping using the X-ray crystallographic structure of complement receptor type 2 (CR2/CD21): identification of a highly inhibitory monoclonal antibody that directly recognizes the CR2-C3d interface. J. Immunol. 2001, 167:5758-5766.
36. Haas K.M., Poe J.C., Steeber D.A., Tedder T.F. B-1a and B-1b cells exhibit distinct developmental requirements and have unique functional roles in innate and adaptive immunity to S. pneumoniae. Immunity. 2005, 23:7-18.
37. Hastings W.D., Gurdak S.M., Tumang J.R., Rothstein T.L. CD5+/Mac-1-peritoneal B cells: a novel B cell subset that exhibits characteristics of B-1 cells. Immunol. Lett. 2006, 105:90-96.
38. Henson S.E., Smith D., Boackle S.A., Holers V.M., Karp D.R. Generation of recombinant human C3dg tetramers for the analysis of CD21 binding and function. J. Immunol. Meth. 2001, 258:97-109.
39. Hess M.W., Schwendinger M.G., Eskelinen E.L., Pfaller K., Pavelka M., Dierich M.P., Prodinger W.M. Tracing uptake of C3dg-conjugated antigen into B cells via complement receptor type 2 (CR2, CD21). Blood 2000, 95:2617-2623.
40. Heyman B., Holmquist G., Borwell P., Heyman U. An enzyme linked immunosorbent assay for measuring anti-sheep erythrocyte antibodies. J. Immunol. Methods 1984, 68:193-204.
41. Heyman B., Wiersma E.J., Kinoshita T. In vivo inhibition of the antibody response by a complement receptor-specific monoclonal antibody. J. Exp. Med. 1990, 172:665-668.
42. Ho J., Moir S., Kulik L., Malaspina A., Donoghue E.T., Miller N.J., Wang W., Chun T.W., Fauci A.S., Holers V.M. Role for CD21 in the establishment of an extracellular HIV reservoir in lymphoid tissues. J. Immunol. 2007, 178:6968-6974.
43. Hoefer M.M., Aichem A., Knight A.M., Illges H. Modulation of murine complement receptor type 2 (CR2/CD21) ectodomain shedding by its cytoplasmic domain. Mol. Immunol. 2008, 45:2127-2137.
44. Holers V.M., Kulik L. Complement receptor 2, natural antibodies and innate immunity: inter-relationships in B cell selection and activation. Mol. Immunol. 2007, 44:64-72.
45. Hsiao F.C., Lin M., Tai A., Chen G., Huber B.T. Cutting edge: Epstein-Barr virus transactivates the HERV-K18 superantigen by docking to the human complement receptor 2 (CD21) on primary B cells. J. Immunol. 2006, 177:2056-2060.
46. Jacobson A.C., Weis J.H. Comparative functional evolution of human and mouse CR1 and CR2. J. Immunol. 2008, 181:2953-2959.
47. Jacobson A.C., Weis J.J., Weis J.H. Complement receptors 1 and 2 influence the immune environment in a B cell receptor-independent manner. J. Immunol. 2008, 180:5057-5066.
48. Kaye J., Bagley J., Malkowski D., Iacomini J. The role of complement receptors in production of antibodies specific for Galalpha1,3Gal. Transplantation 2004, 77:314-316.
49. Kozono Y., Abe R., Kozono H., Kelly R.G., Azuma T., Holers V.M. Cross-linking CD21/CD35 or CD19 increases both B7-1 and B7-2 expression on murine splenic B cells. J. Immunol. 1998, 160:1565-1572.
50. Kuhn K.A., Cozine C.L., Tomooka B., Robinson W.H., Holers V.M. Complement receptor CR2/CR1 deficiency protects mice from collagen-induced arthritis and associates with reduced autoantibodies to type II collagen and citrullinated antigens. Mol. Immunol. 2008, 45:2808-2819.
51. Kulik L., Marchbank K.J., Lyubchenko T., Kuhn K.A., Liubchenko G.A., Haluszczak C., Gibson M.G., Boackle S.A., Holers V.M. Intrinsic B cell hypo-responsiveness in mice prematurely expressing human CR2/CD21 during B cell development. Eur. J. Immunol. 2007, 37:623-633.
52. Kurtz C.B., O'Toole E., Christensen S.M., Weis J.H. The murine complement receptor gene family. IV. Alternative splicing of Cr2 gene transcripts predicts two distinct gene products that share homologous domains with both human CR2 and CR1. J. Immunol. 1990, 144:3581-3591.
53. Lee Y., Haas K.M., Gor D.O., Ding X., Karp D.R., Greenspan N.S., Poe J.C., Tedder T.F. Complement component C3d-antigen complexes can either augment or inhibit B lymphocyte activation and humoral immunity in mice depending on the degree of CD21/CD19 complex engagement. J. Immunol. 2005, 175:8011-8023.
54. Leslie R.G., Prodinger W.M., Nielsen C.H. Complement receptors type 1 (CR1, CD35) and 2 (CR2, CD21) cooperate in the binding of hydrolyzed complement factor 3 (C3i) to human B lymphocytes. Eur. J. Immunol. 2003, 33:3311-3321.
55. Leslie R.G.Q. The influence of complement receptor type 1 (CD35) and decay-accelerating factor (CD55) on complement receptor type 2-(CD21) mediated alternative pathway activation by B cells. Immunology 1999, 97:371-373.
56. Lobner M., Leslie R.G., Prodinger W.M., Nielsen C.H. Spontaneous complement activation on human B cells results in localized membrane depolarization and the clustering of complement receptor type 2 and C3 fragments. Immunology 2009, 128:e661-e669.
57. Lottin-Divoux S., Jean D., Le R.M., Frade R. Activation of Epstein-Barr virus/C3d receptor (gp140, CR2, CD21) on human B lymphoma cell surface triggers Cbl tyrosine phosphorylation, its association with p85 subunit, Crk-L and Syk and its dissociation with Vav. Cell Signal. 2006, 18:1219-1225.
58. Luxembourg A.T., Cooper N.R. Modulation of signaling via the B cell antigen receptor by CD21, the receptor for C3dg and EBV. J. Immunol. 1994, 153:4448-4457.
59. Lyubchenko T., dal Porto J., Cambier J.C., Holers V.M. Co-ligation of the B cell receptor with complement receptor type 2 (CR2/CD21) using its natural ligand C3dg: activation without engagement of an inhibitory signaling pathway. J. Immunol. 2005, 174:3264-3272.
60. Lyubchenko T., Dal Porto J.M., Holers V.M., Cambier J.C. Cutting edge: Complement (C3d)-linked antigens break B cell anergy. J. Immunol. 2007, 179:2695-2699.
61. Manderson A.P., Quah B., Botto M., Goodnow C.C., Walport M.J., Parish C.R. A novel mechanism for complement activation at the surface of B cells following antigen binding. J. Immunol. 2006, 177:5155-5162.
62. Marchbank K.J., Kulik L., Gipson M.G., Morgan B.P., Holers V.M. Expression of human complement receptor type 2 (CR2/CD21) in mice during early B cell development results in a reduction in mature B cells and hypogammaglobulinemia. J. Immunol. 2002, 169:3526-3535.
63. Marchbank K.J., Watson C.C., Ritsema D.F., Holers V.M. Expression of human complement receptor 2 (CR2/CD21) in Cr2-/- mice restores humoral immune function. J. Immunol. 2000, 165:1354-2361.
64. Masilamani M., Kassahn D., Mikkat S., Glocker M.O., Illges H. B cell activation leads to shedding of complement receptor type II (CR2/CD21). Eur. J. Immunol. 2003, 33:2391-2397.
65. Molina H., Kinoshita T., Inoue K., Carel J.-C., Holers V.M. A molecular and immunochemical characterization of mouse CR2: evidence for a single gene model of mouse Complement Receptors 1 and 2. J. Immunol. 1990, 145:2974-2983.
66. Molina H., Kinoshita T., Webster C.B., Holers V.M. Analysis of C3b/C3d binding sites and factor I cofactor regions within mouse complement receptors 1 and 2. J. Immunol. 1994, 153:789-795.
67. Molnar E., Erdei A., Prechl J. Novel roles for murine complement receptors type 1 and 2 I. Regulation of B cell survival and proliferation by CR1/2. Immunol. Lett. 2008, 116:156-162.
68. Molnar E., Prechl J., Erdei A. Novel roles for murine complement receptors type 1 and 2 II. Expression and function of CR1/2 on murine mesenteric lymph node T cells. Immunol. Lett. 2008, 116:163-167.
69. Moore M.D., Cooper N.R., Tack B.F., Nemerow G.R. Molecular cloning of the cDNA encoding the Epstein-Barr virus/C3d receptor (complement receptor type 2) of human B lymphocytes. Proc. Natl. Acad. Sci. U. S. A. 1987, 84:9194-9198.
70. Nemerow G.R., Wolfert R., McNaughton M.E., Cooper N.R. Identification and characterization of the Epstein-Barr virus receptor on human B lymphocytes and its relationship to the C3d complement receptor (CR2). J. Virol. 1985, 55:347-351.
71. Nielsen C.H., Marquart H.V., Prodinger W.M., Leslie R.G. CR2-mediated activation of the complement alternative pathway results in formation of membrane attack complexes on human B lymphocytes. Immunology 2001, 104:418-422.
72. Nielsen C.H., Matthiesen S.H., Lyng I., Leslie R.G. The role of complement receptor type 1 (CR1, CD35) in determining the cellular distribution of opsonized immune complexes between whole blood cells: kinetic analysis of the buffering capacity of erythrocytes. Immunology 1997, 90:129-137.
73. Phan T.G., Grigorova I., Okada T., Cyster J.G. Subcapsular encounter and complement-dependent transport of immune complexes by lymph node B cells. Nat. Immunol. 2007, 8:992-1000.
74. Poe J.C., Hagesawa M., Tedder T.F. CD19, CD21, and CD22: multifaceted response regulators of B lymphocyte signal transduction. Intl. Rev. Immunol. 2001, 20:739-762.
75. Pozdnyakova O., Guttormsen H.K., Lalani F.N., Carroll M.C., Kasper D.L. Impaired antibody response to group B streptococcal type III capsular polysaccharide in C3- and complement receptor 2-deficient mice. J. Immunol. 2003, 170:84-90.
76. Prodeus A., Goerg S., Shen L., Pozdnyakova O.O., Alicot E.M., Goodnow C.C., Carroll M.C. A critical role of complement in regulation of self-reactive B cells. Mol. Immunol. 1998, 35:338. (abstract).
77. Prodeus A., Goerg S., Shen L.-M., Pozdnyakova O.O., Chu L., Alicot E.M., Goodnow C.C., Carroll M.C. A critical role for complement in maintenance of self-tolerance. Immunity 1998, 9:721-731.
78. Reid R.R., Woodstock S., Shimabukuro-Vornhagen A., Austen W.G., Kobzik L., Zhang M., Hechtman H.B., Moore F.D., Carroll M.C. Functional activity of natural antibody is altered in Cr2-deficient mice. J. Immunol. 2002, 169:5433-5440.
79. Ross G.D., Medof M.E. Membrane complement receptors specific for bound fragments of C3. Adv. Immunol. 1985, 37:217-267.
80. Rothstein T.L. Cutting edge commentary: two B-1 or not to be one. J. Immunol. 2002, 168:4257-4261.
81. Szomolanyi-Tsuda E., Seedhom M.O., Carroll M.C., Garcea R.L. T cell-independent and T cell-dependent immunoglobulin G responses to polyomavirus infection are impaired in complement receptor 2-deficient mice. Virology 2006, 352:52-60.
82. Takahashi K., Kozono Y., Waldschmidt T.J., Berthiaume D., Quigg R.J., Baron A., Holers V.M. Mouse complement receptors type 1 (CR1; CD35) and type 2 (CR2; CD21): expression on normal B cell subpopulations and decreased levels during the development of autoimmunity in MRL/lpr mice. J. Immunol. 1997, 159:1557-1569.
83. Tedder T.F., Zhou L.-J., Engel P. The CD19/CD21 signal transduction complex of B lymphocytes. Immunol. Today 1994, 15:437-442.
84. Tessier J., Cuvillier A., Glaudet F., Khamlichi A.A. Internalization and molecular interactions of human CD21 receptor. Mol. Immunol. 2007, 44:2415-2425.
85. Thornton B.P., Vetvicka V., Ross G.D. Function of C3 in a humoral response: iC3b/C3dg bound to an immune complex generated with natural antibody and a primary antigen promotes antigen uptake and the expression of co-stimulatory molecules by all B cells, but only stimulates immunoglobulin synthesis by antigen-specific B cells. Clin. Exp. Immunol. 1996, 104:531-537.
86. Tsubata T. Co-receptors on B lymphocytes. Curr. Opin. Immunol. 1999, 11:249-255.
87. Tuveson D.A., Ahearn J.M., Matsumoto A.K., Fearon D.T. Molecular interactions of complement receptors on B lymphocytes: a CR1/CR2 complex distinct from the CR2/CD19 complex. J. Exp. Med. 1991, 173:1083-1089.
88. Twohig J., Kulik L., Haluszczak C., Reuter J., Rossbach A., Bull M., Holers V.M., Marchbank K.J. Defective B cell ontogeny and immune response in human complement receptor 2 (CR2, CD21) transgenic mice is partially recovered in the absence of C3. Mol. Immunol. 2007, 44:3434-3444.
89. Weis J.J., Richards S.A., Smith J.A., Fearon D.T. Purification of the B lymphocyte receptor for the C3d fragment of complement and the Epstein-Barr virus by monoclonal antibody affinity chromatography, and assessment of its functional capacities. J. Immunol. Methods 1986, 92:79-87.
90. Whipple E.C., Ditto A.H., Shanahan R.S., Gatesman J.J., Little S.F., Taylor R.P., Lindorfer M.A. Low doses of antigen coupled to anti-CR2 mAbs induce rapid and enduring IgG immune responses in mice and in cynomolgus monkeys. Mol. Immunol. 2007, 44:377-388.
91. Wu X., Jiang N., Fang Y.F., Xu C., Mao D., Singh J., Fu Y.X., Molina H. Impaired affinity maturation in Cr2-/- mice is rescued by adjuvants without improvement in germinal center development. J. Immunol. 2000, 165:3119-3127.